The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience
The Breast Journal · 2023
DOI: 10.1155/2023/4549033 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Breast Journal, 2023. Verfasst von Ismail Can Tercan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey. Hauptthemen laut MEDLINE: Sentinel Lymph Node Biopsy, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To evaluate the efficiency and safety of sentinel lymph node biopsy (SLNB) in patients with breast cancer with complete response to neoadjuvant chemotherapy (NAC).
Methods
Ninety-two consecutive (T1-4 and N1-2) patients with breast cancer who had pathologic and/or clinical and radiologic axillary lymph node involvement were included. All patients received NAC. Patients with a clinical and radiologic complete response in the axilla after NAC underwent SLNB. Pathologic complete response (ypCR) was defined as the absence of residual invasive and in situ cancer, and near-complete response (ypNCR) represented in situ and/or ≤ 1 mm residual tumor in the breast and/or presence of malignant cell clusters (≤0.2 mm) and/or micrometastases (≤2.0 mm) in the axillary lymph nodes (ALN) (ypTis/T1mi, ypN0i+/pN1mi).
Results
The mean age of the 92 patients was 49.6 ± 10.3 years and the mean follow-up was 34.0 ± 17.8 months. With respect to breast tumors, 23 (25.0%) patients had complete and 14 (15.2%) had a near-complete response to NAC. Complete response in ALN was obtained in 39 (42.4%) patients and near-complete in six (6.5%) patients. The overall survival of the 33 patients who achieved ypCR and ypNCR was 100% and the remaining 59 patients with partial or no response to NAC was 83.1% at a mean follow-up of 34 months ( p = 0.063 ).
Conclusions
In this study, no event developed in cases with ypCR and ypNCR in the breast and axilla. The persistence of the same results in long-termfollow-ups may enable the use of ypNCR as a positive prognostic marker in addition to ypCR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of General Surgery, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.
- Department of Medical Oncology, Izmir Bozyaka Health Practice and Research Center, Izmir, Turkey.
- Department of Pathology, Izmir Bozyaka Health Practice and Research Center, Izmir, Turkey.
- Department of Radiology, Izmir Bozyaka Health Practice and Research Center, Izmir, Turkey.
- Department of Public Health, Ege University, Medical Faculty, Izmir, Turkey.
ORCID-Profile: Ismail Can Tercan, Baha Zengel, Ozlem Ozdemir, Demet Cavdar, Funda Tasli, Zehra Hilal Adibelli, Murat Karatas, Cenk Simsek, Isabel Raika Durusoy, Adam Uslu
Zitieren
APA
Tercan, I. C., Zengel, B., Ozdemir, O., Cavdar, D., Tasli, F., Adibelli, Z. H., Karatas, M., Simsek, C., Durusoy, I. R., & Uslu, A. (2023). The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience. The Breast Journal. https://doi.org/10.1155/2023/4549033
Vancouver
Tercan IC, Zengel B, Ozdemir O, Cavdar D, Tasli F, Adibelli ZH, et al. The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience. The Breast Journal. 2023. doi:10.1155/2023/4549033
BibTeX
@article{Tercan2023,
author = {Tercan, Ismail Can and Zengel, Baha and Ozdemir, Ozlem and Cavdar, Demet and Tasli, Funda and Adibelli, Zehra Hilal and Karatas, Murat and Simsek, Cenk and Durusoy, Isabel Raika and Uslu, Adam},
title = {The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience},
journal = {The Breast Journal},
year = {2023},
doi = {10.1155/2023/4549033}
}
EUVIMED